Novartis has officially launched a new aseptic manufacturing facility in Ljubljana, marking a significant expansion of its operations in Slovenia. This state-of-the-art plant, spanning 17,000 square meters, is designed to produce and package a wide range of aseptic products, including both liquid and freeze-dried medicines. The facility is equipped with cutting-edge technologies such as isolator systems, lyophilization units, and automated assembly lines, enabling it to manufacture over 30 million syringes and vials annually. This level of production capacity underscores Novartis’s commitment to maintaining high standards of safety and efficiency in drug manufacturing.
The timing of the facility's opening is notable, coming just under two years after the inauguration of another major project—Novartis’s viral vector production facility in Mengeš, located approximately 20 kilometers north of Ljubljana. That facility, which cost around €40 million, was the company’s first of its kind in Europe and focused on producing vaccines and other therapeutic agents using advanced gene-editing techniques. Now, with the new aseptic manufacturing site, Novartis continues to solidify its presence in Slovenia, reinforcing the country's role as a strategic location within the company's global operations.
In addition to these developments, Novartis has recently completed another important investment in the region. Less than a month prior to the opening of the new facility, Sandoz—a former division of Novartis that now operates independently—announced the completion of a $99 million biosimilars development center in Ljubljana. This center is part of a larger plan to establish an end-to-end biosimilar development and manufacturing hub in Europe, further enhancing Slovenia’s position as a key player in the pharmaceutical industry.
The new aseptic manufacturing facility employs a team of 300 highly specialized professionals, including experts in aseptic manufacturing, engineering, quality assurance, automation, and supply chain management. These individuals play a crucial role in ensuring that the facility meets stringent regulatory requirements and maintains the highest levels of product purity and safety. The facility also includes a central quality control laboratory capable of conducting up to one million microbial tests per year, providing essential support for all Novartis sites across Slovenia and contributing to ongoing research and development efforts in the country.
Dr. Petra Štefanič Anderluh, the CEO of Novartis’s Slovenian subsidiary, emphasized the significance of the facility, stating that it represents a testament to Slovenia’s exceptional expertise and dedication. She noted that the launch is part of a broader €600 million investment cycle executed in recent years, which has significantly enhanced the company’s regional capabilities in research and advanced manufacturing. This investment cycle reflects Novartis’s long-term vision for Slovenia as a vital component of its global strategy.
Economy Minister Anže Logar also praised the pharmaceutical sector as a cornerstone of the future economy, highlighting Slovenia’s leading position in Central and Eastern Europe and its ranking as ninth in the European Union for pharmaceutical manufacturing. He underscored the importance of continued investment in the sector, emphasizing that a stable and competitive business environment is essential for attracting and retaining top-tier companies like Novartis.
Looking ahead, the new facility is expected to contribute substantially to Slovenia’s economic growth and technological advancement. With its focus on innovation and precision manufacturing, the plant is poised to become a model for sustainable and efficient pharmaceutical production. As Novartis continues to expand its footprint in the region, the success of this facility could serve as a catalyst for further investments and collaborations, reinforcing Slovenia’s reputation as a leader in the global pharmaceutical landscape.
3 reports
The Slovenia TimesIndependentCenteryesterdayNovartis has opened a new aseptic manufacturing facility in Ljubljana, Slovenia, adding to the company's significant investments in the country. The facility spans 17,000 square meters and will produce and package liquid and freeze-dried medicines, with an annual capacity of over 30 million syringes and vials. It includes a central quality control laboratory serving all Novartis sites in Slovenia and will initially employ 300 highly skilled workers. This project is part of a larger €600 million investment by Novartis in Slovenia over recent years, aimed at enhancing regional research and development and manufacturing capabilities. Economy Minister Anže Logar emphasized the importance of the pharmaceutical sector for Slovenia's future economic growth, noting the country's strong position in pharmaceutical manufacturing within Central and Eastern Europe and the EU. The new facility follows other recent investments, such as a €40 million viral vector production plant in Mengeš and a $99 million biosimilars development center by Sandoz in Ljubljana.
Bias read (Center): The article focuses on a business-related development involving a pharmaceutical company's investment in Slovenia. There is no explicit political framing, ideological emphasis, or partisan language. The content is descriptive and highlights economic benefits and technical specifications without bias
DeloIndependent🔒CenteryesterdayThe article discusses the opening of a new aseptic production facility by Novartis in Ljubljani, Slovenia, which will employ over 300 specialists. The facility features advanced isolation filling lines, automated control systems, and a microbiological laboratory capable of conducting approximately half a million tests annually. It highlights the technological sophistication of the plant, emphasizing its role in producing biological medicines and RNA-based therapies. The investment underscores Novartis' confidence in Slovenian expertise and its commitment to innovation. Key figures such as Dr. Petra Štefanič Anderluh and Manka Cirk describe the facility's importance within the pharmaceutical industry and its contribution to global healthcare.
Bias read (Center): While the article covers a significant economic development involving a multinational corporation, it does not present overtly partisan perspectives or frame the issue along ideological lines. The focus remains on technical and operational aspects of the facility, with no clear leaning toward either
STA – Slovenska tiskovna agencijaState / PublicCenteryesterdayNovartis je v Ljubljani odprt nov obrat za aseptično proizvodnjo, kar predstavlja novo zgradbo za proizvodnjo zdravil s povečanimi strogo higieničnimi standardi. Obrat bo omogočil večjo kapaciteto in boljšo učinkovitost v procesu proizvodnje zdravil. Ta zgradba je del širše strategije podjetja za izboljšanje svojih proizvodnih moči na trgu. Vzajemni partnerji in lokalne občine so bili vključeni v proces razvoja projekta.
Bias read (Center): Artikel opisuje ekonomsko dogodki, ki so povezani z delovanjem podjetja, kar ni politično polemljeno. Kljub temu se ne nanaša na politične stranke ali vlado, zato se ne more klasificirati kot politično polemljen. Poudarek je na poslovni aktivnosti in infrastrukturi, kar kaže na neutralno stališče.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
Slovenia
